The Global DNA and RNA Banking Services Market is projected to reach $12.96 billion by 2028, from a value of $7.56 billion in 2022, by registering a CAGR of 8.0% during the forecast period. The increasing number of newly constructed and recently functioning imaging biobanks serves, the advancement of digital systems, and the conversion of biobanks to fully automated biobanks are the major factors propelling the growth of the market. However, ethical and legal issues are hampering the market growth. Moreover, with advancements in medical imaging and the use of computed tomography for the identification and validation of non-invasive biomarkers for collecting images, an increasing number of newly constructed and recently functioning imaging biobanks are creating ample opportunities across the globe.
Recent Developments
In Jun 2022, GoodCell, launched Personal Biobanking, a proactive, preventative healthcare service that allows members to store their own stem cells for potential future personalized therapy.
In January 2020, Brooks Life Sciences expanded its facilities in order to increase sample storage and biobanking. Research institutes and pharmaceutical companies were able to accelerate clinical studies and the development of effective treatments by collecting a larger volume of samples.
In June 2021, Thermo Fisher Scientific’s (TMO) launched upgraded Quick to Clinic solution to balance speed and quality to accelerate and advance DNA to Investigational New Drug status in as little as 13 months. With this solution, emerging biopharma companies working on early development can now leverage a lab-to-clinic drug development solution designed to accelerate the journey from DNA to drug product.
Competitive Landscape
US Biolab Corporation Inc, Thermo Fisher Scientific Inc, ProteoGenex , PreventionGenetics, LGC Biosearch Technologies, Infinity Biologix, GoodCell, EasyDNA, DNA Genotek Inc, deCODE genetics, Brooks Life Sciences, 23andMe Inc are some of the major players in the Global DNA and RNA Banking Services Market.
